A Phase 1 interventional study of DS-1205c and Osimertinib in Non-small Cell Lung Cancer (NSCLC), sponsored by Daiichi Sankyo. Terminated at 7 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-19.
Sponsored by Daiichi Sankyo · Phase 1, Interventional, and Treatment
How we know · 8 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo — 5 open to participants now, 16 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Daiichi Sankyo.
Among the 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo, this one is the 31st largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2019, is one of 10 in phase 1, and was the 15th registered.
7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →5 of the 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo are open now, in 12 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Taiwan
Ages 18+
Daiichi Sankyo · Sites in United States, Argentina, Austria and 10 more countries
Ages 18+
Daiichi Sankyo · Sites in United States, Argentina, Belgium and 21 more countries
Ages 18+
Daiichi Sankyo · Sites in China
Ages 18+
Daiichi Sankyo · Sites in United States, Australia, Belgium and 13 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 15 · Phase 3 8
First in 1999; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 181 across the 31 interventional studies, 681 across the 6 observational. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 37 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.
1 of the studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06809764Daiichi SankyoClinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN) | 2027-02-12 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies in Carcinoma, Non-Small-Cell Lung by Daiichi Sankyo, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study has two parts: dose escalation and dose expansion.
The primary objectives are:
In Dose Escalation, after a 7-day run in period (Cycle 0), there will be 21-day cycles (Cycle 1 onward). In Dose Expansion, there will be 21-day cycles.
The number of treatment cycles is not fixed in this study. Participants will continue study treatment until they decide not to (withdraw consent), their disease gets worse [progressive disease (PD)], or side effects become unacceptable (unacceptable toxicity).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has acquired resistance to EGFR TKI according to the Jackman criteria (PMID: 19949011):
Exclusion Criteria:
Has received treatment with any of the following:
Has history of other active within 3 years prior to enrollment, except:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 800 mg, 1200 mg) in combination with daily 80 mg oral dose of osimertinib
Drug: DS-1205c · Drug: Osimertinib
DS-1205c 200 mg capsule
Osimertinib 80 mg tablet
Number of Participants With Dose-limiting Toxicities (DLTs) Following Administration With DS-1205c in Combination With Osimertinib
A dose-limiting toxicity (DLT) was defined as any TEAE not attributable to disease or disease-related processes that occurred during the DLT-evaluation period (Cycle 0, Day 1 to Cycle 1, Day 21 of Dose Escalation) and was Grade 3 or above, according to NCI-CTCAE Version 5.0.
Time frame: Cycle 0, Day 1 (7-day cycle) to Cycle 1, Day 21 of Dose Escalation (each cycle was 21 days)
Number of Participants With Treatment-emergent Adverse Events Occurring in More Than 1 Participant Following Administration With DS-1205c in Combination With Osimertinib
Treatment-emergent adverse events were defined as an adverse event (AE) that occurs, having been absent before the first dose of study drug, or has worsened in severity after the initiating the study drug until 30 days after last dose of the study drug.
Time frame: Screening; Cycle 0 (7-day cycle), Days -1, 1, 2, 4, 6, and 7; Cycle 1 (21-day cycle), Days 4, 8, and 15; Cycle 2 (21-day cycle), Days 1, 2, and 8; Cycle 3 and beyond (21-day cycles), Day 1; and end-of-treatment, 30 days after last dose, up to 1 year
Number of Participants With Best Overall Response Assessed by Investigator Following Administration of DS-1205c in Combination With Osimertinib
Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Objective response rate is calculated as the number of participants with best objective response \[complete response (CR) or partial response (PR) determined by Investigator assessment based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1\], divided by the number of participants in the analysis population.
Time frame: Screening; Cycle 0 (7-day cycle); Cycle 1 and beyond (21-day cycles), Every 6 weeks (± 7 days) in the first 24 weeks after Day 1 of Cycle 1, and every 12 weeks (± 7 days) thereafter; and end-of-treatment, 30 days after last dose, up to 1 year
Disease Control Rate Assessed by Investigator Following Administration of DS-1205c in Combination With Osimertinib
Disease control rate (DCR) is defined as the sum of complete response (CR) rate, partial response (PR) rate, and stable disease (SD) rate. As per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.
Time frame: Screening; Cycle 0 (7-day cycle); Cycle 1 and beyond (21-day cycles), Every 6 weeks (± 7 days) in the first 24 weeks after Day 1 of Cycle 1, and every 12 weeks (± 7 days) thereafter; and end-of-treatment, 30 days after last dose, up to 1 year
Progression-free Survival Assessed by Investigator Following Administration of DS-1205c in Combination With Osimertinib
Progression-free survival is defined as the time from the date of first dose to the earliest date of the first objective documentation of disease progression or death due to any cause. As per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions.
Time frame: Screening; Cycle 0 (7-day cycle); Cycle 1 and beyond (21-day cycles), Every 6 weeks (± 7 days) in the first 24 weeks after Day 1 of Cycle 1, and every 12 weeks (± 7 days) thereafter; and end-of-treatment, 30 days after last dose, up to 1 year
Overall Survival in Participants Following Administration of DS-1205c in Combination With Osimertinib
Overall survival was defined as the time from the date of first dose to the date of death due to any cause.
Time frame: Screening; Cycle 0 (7-day cycle); Cycle 1 and beyond (21-day cycles), Every 6 weeks (± 7 days) in the first 24 weeks after Day 1 of Cycle 1, and every 12 weeks (± 7 days) thereafter; and end-of-treatment, 30 days after last dose, up to 1 year
Maximum Concentration (Cmax) Following Administration of DS-1205c Alone and in Combination With Osimertinib
The maximum concentration (Cmax) of DS-1205c alone and in combination with osimertinib was assessed. Pharmacokinetic (PK) parameters for each participant were estimated using non-compartmental analysis. Descriptive statistics are provided for all plasma concentration data by analyte/dose/study day/time and for each PK parameter by analyte/dose/study day, as appropriate.
Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours of Cycle 0 (7-day cycle; DS-1205c alone), Day 1; Predose, 1, 2, 4, 6, 8, and 10 hours of Cycle 0, Day 7 (DS-1205c alone); Predose, 1, 2, 4, 6, 8, 10, and 12 hours of Cycle 2 (21-day cycle), Day 1 (DS-1205c+osimertinib)
Area Under the Plasma Concentration Curve Following Administration of DS-1205c Alone and in Combination With Osimertinib
The area under the plasma concentration curve from time 0 until last quantifiable time point (AUClast) and the area under the plasma concentration curve over a dosing interval (AUCtau) of DS-1205c alone and in combination with osimertinib were assessed. Pharmacokinetic (PK) parameters for each participant were estimated using non-compartmental analysis. Descriptive statistics are provided for all plasma concentration data by analyte/dose/study day/time and for each PK parameter by analyte/dose/study day, as appropriate.
Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours of Cycle 0 (7-day cycle; DS-1205c alone), Day 1; Predose, 1, 2, 4, 6, 8, and 10 hours of Cycle 0, Day 7 (DS-1205c alone); Predose, 1, 2, 4, 6, 8, 10, and 12 hours of Cycle 2 (21-day cycle), Day 1 (DS-1205c+osimertinib)
Time to Maximum Concentration (Tmax) Following Administration of DS-1205c Alone and in Combination With Osimertinib
The time to maximum concentration (Tmax) of DS-1205c alone and in combination with osimertinib was assessed. Pharmacokinetic (PK) parameters for each participant were estimated using non-compartmental analysis. Descriptive statistics are provided for all plasma concentration data by analyte/dose/study day/time and for each PK parameter by analyte/dose/study day, as appropriate.
Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours of Cycle 0 (7-day cycle; DS-1205c alone), Day 1; Predose, 1, 2, 4, 6, 8, and 10 hours of Cycle 0, Day 7 (DS-1205c alone); Predose, 1, 2, 4, 6, 8, 10, and 12 hours of Cycle 2 (21-day cycle), Day 1 (DS-1205c+osimertinib)
Trough Plasma Concentration (Ctrough) Following Administration of DS-1205c Alone and in Combination With Osimertinib
The trough plasma concentration (Ctrough) of DS-1205c alone and in combination with osimertinib was assessed. Pharmacokinetic (PK) parameters for each participant were estimated using non-compartmental analysis. Descriptive statistics are provided for all plasma concentration data by analyte/dose/study day/time and for each PK parameter by analyte/dose/study day, as appropriate.
Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours of Cycle 0 (7-day cycle; DS-1205c alone), Day 1; Predose, 1, 2, 4, 6, 8, and 10 hours of Cycle 0, Day 7 (DS-1205c alone); Predose, 1, 2, 4, 6, 8, 10, and 12 hours of Cycle 2 (21-day cycle), Day 1 (DS-1205c+osimertinib)
Terminal Half-life (t1/2) Following Administration of DS-1205c Alone and in Combination With Osimertinib
The terminal half-life (t1/2) of DS-1205c alone and in combination with osimertinib was assessed. Pharmacokinetic (PK) parameters for each participant were estimated using non-compartmental analysis. Descriptive statistics are provided for all plasma concentration data by analyte/dose/study day/time and for each PK parameter by analyte/dose/study day, as appropriate.
Time frame: Predose, 1, 2, 4, 6, 8, and 12 hours of Cycle 0 (7-day cycle; DS-1205c alone), Day 1; Predose, 1, 2, 4, 6, 8, and 10 hours of Cycle 0, Day 7 (DS-1205c alone); Predose, 1, 2, 4, 6, 8, 10, and 12 hours of Cycle 2 (21-day cycle), Day 1 (DS-1205c+osimertinib)
A total of 13 participants who met all inclusion criteria and no exclusion criteria were enrolled from 10 April 2019 to 04 September 2020 in the study at 7 clinical sites in Taiwan.
| Milestone | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib |
|---|---|---|---|---|
| Started | 6 | 3 | 3 | 1 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 6 | 3 | 3 | 1 |
| Withdrew: Clinical progression | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Progressive disease by recist version 1.1 | 4 | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 | 0 |
A dose-limiting toxicity (DLT) was defined as any TEAE not attributable to disease or disease-related processes that occurred during the DLT-evaluation period (Cycle 0, Day 1 to Cycle 1, Day 21 of Dose Escalation) and was Grade 3 or above, according to NCI-CTCAE Version 5.0.
| Participants | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib |
|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs) Following Administration With DS-1205c in Combination With Osimertinib | 1 | 0 | 0 | 0 |
Treatment-emergent adverse events were defined as an adverse event (AE) that occurs, having been absent before the first dose of study drug, or has worsened in severity after the initiating the study drug until 30 days after last dose of the study drug.
| Participants | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib |
|---|---|---|---|---|
| Any TEAEs | 6 | 3 | 3 | 1 |
| Upper respiratory tract infection | 2 | 0 | 1 | 0 |
| Urinary tract infection | 2 | 1 | 0 | 0 |
| Pneumonia | 1 | 0 | 0 | 1 |
| Anaemia | 0 | 1 | 1 | 1 |
| Insomnia | 1 | 2 | 1 | 0 |
| Dizziness | 1 | 1 | 0 | 0 |
| Headache | 1 | 0 | 1 | 0 |
| Cough | 1 | 1 | 0 | 0 |
| Dyspnoea | 1 | 1 | 0 | 0 |
| Haemoptysis | 1 | 1 | 0 | 0 |
| Vomiting | 3 | 1 | 0 | 0 |
| Diarrhoea | 0 | 1 | 2 | 0 |
| Constipation | 2 | 0 | 0 | 0 |
| Rash | 1 | 1 | 0 | 0 |
| Fatigue | 1 | 2 | 0 | 0 |
| Pyrexia | 0 | 0 | 2 | 0 |
| Alanine aminotransferase increased | 1 | 0 | 1 | 1 |
| Aspartate aminotransferase increased | 1 | 0 | 1 | 1 |
| Blood Creatinine Phosphokinase Increased | 0 | 1 | 1 | 1 |
| Blood Creatinine Increased | 0 | 1 | 1 | 0 |
| Ejection Fraction Decreased | 0 | 1 | 1 | 0 |
| Lipase Increased | 0 | 0 | 1 | 1 |
| Overdose | 0 | 0 | 2 | 0 |
Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Objective response rate is calculated as the number of participants with best objective response \[complete response (CR) or partial response (PR) determined by Investigator assessment based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1\], divided by the number of participants in the analysis population.
| Participants | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib |
|---|---|---|---|---|
| Complete response (CR) | 0 | 0 | 0 | 0 |
| Partial response (PR) | 0 | 0 | 0 | 0 |
| Stable disease (SD) | 2 | 3 | 3 | 1 |
| Progressive disease (PD) | 3 | 0 | 0 | 0 |
| Not evaluable (NE) | 1 | 0 | 0 | 0 |
| Overall response rate (ORR) | 0 | 0 | 0 | 0 |
Disease control rate (DCR) is defined as the sum of complete response (CR) rate, partial response (PR) rate, and stable disease (SD) rate. As per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.
| Participants | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib |
|---|---|---|---|---|
| Disease Control Rate Assessed by Investigator Following Administration of DS-1205c in Combination With Osimertinib | 2 | 3 | 3 | 1 |
Progression-free survival is defined as the time from the date of first dose to the earliest date of the first objective documentation of disease progression or death due to any cause. As per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions.
| weeks | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib |
|---|---|---|---|---|
| Progression-free Survival Assessed by Investigator Following Administration of DS-1205c in Combination With Osimertinib | 7.1 (5.4 to 36.6) | NA (12.3 to NA) | 22.0 (12.1 to 22.0) | 12.4 (NA to NA) |
Overall survival was defined as the time from the date of first dose to the date of death due to any cause.
| weeks | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib |
|---|---|---|---|---|
| Overall Survival in Participants Following Administration of DS-1205c in Combination With Osimertinib | 46.9 (34.0 to NA) | NA (14 to NA) | NA (32 to NA) | NA (NA to NA) |
The maximum concentration (Cmax) of DS-1205c alone and in combination with osimertinib was assessed. Pharmacokinetic (PK) parameters for each participant were estimated using non-compartmental analysis. Descriptive statistics are provided for all plasma concentration data by analyte/dose/study day/time and for each PK parameter by analyte/dose/study day, as appropriate.
| ng/mL | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib |
|---|---|---|---|---|
| Cycle 0: Day 1 | 292 ± 94.8 | 413 ± 94.0 | 499 ± 222 | 703 ± NA |
| Cycle 0: Day 7 | 561 ± 191 | 827 ± 299 | 1041 ± 460 | 1070 ± NA |
| Cycle 2: Day 1 | 544 ± 176 | 845 ± 328 | 921 ± 260 | 1150 ± NA |
The area under the plasma concentration curve from time 0 until last quantifiable time point (AUClast) and the area under the plasma concentration curve over a dosing interval (AUCtau) of DS-1205c alone and in combination with osimertinib were assessed. Pharmacokinetic (PK) parameters for each participant were estimated using non-compartmental analysis. Descriptive statistics are provided for all plasma concentration data by analyte/dose/study day/time and for each PK parameter by analyte/dose/study day, as appropriate.
| h*ng/mL | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib |
|---|---|---|---|---|
| AUClast, Cycle 0: Day 1 | 1916 ± 530 | 2493 ± 277 | 2891 ± 1398 | 5050 ± NA |
| AUClast, Cycle 0: Day 7 | 4193 ± 1514 | 5716 ± 1931 | 7385 ± 4562 | 8602 ± NA |
| AUClast, Cycle 2: Day 1 | 4445 ± 1389 | 6852 ± 2716 | 7220 ± 2629 | 9495 ± NA |
| AUCtau, Cycle 0: Day 1 | 1975 ± 563 | 2557 ± 257 | 3002 ± 1472 | 5255 ± NA |
| AUCtau, Cycle 0: Day 7 | 4818 ± 1772 | 6496 ± 2208 | 6972 ± NA | 10300 ± NA |
| AUCtau, Cycle 2: Day 1 | 4596 ± 1488 | 7117 ± 2883 | 7640 ± 2918 | 10000 ± NA |
The time to maximum concentration (Tmax) of DS-1205c alone and in combination with osimertinib was assessed. Pharmacokinetic (PK) parameters for each participant were estimated using non-compartmental analysis. Descriptive statistics are provided for all plasma concentration data by analyte/dose/study day/time and for each PK parameter by analyte/dose/study day, as appropriate.
| hours | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib |
|---|---|---|---|---|
| Cycle 0: Day 1 | 4.1 (2.0 to 6.0) | 4.0 (3.9 to 4.0) | 3.9 (2.0 to 4.0) | 6.2 (6.2 to 6.2) |
| Cycle 0: Day 7 | 4.0 (2.0 to 4.2) | 4.0 (2.1 to 4.0) | 4.0 (3.9 to 5.9) | 4.0 (4.0 to 4.0) |
| Cycle 2: Day 1 | 4.1 (4.0 to 4.2) | 4.0 (2.0 to 4.1) | 2.1 (0 to 4.0) | 3.9 (3.9 to 3.9) |
The trough plasma concentration (Ctrough) of DS-1205c alone and in combination with osimertinib was assessed. Pharmacokinetic (PK) parameters for each participant were estimated using non-compartmental analysis. Descriptive statistics are provided for all plasma concentration data by analyte/dose/study day/time and for each PK parameter by analyte/dose/study day, as appropriate.
| ng/mL | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib |
|---|---|---|---|---|
| Cycle 0: Day 7 | 376 ± 143 | 460 ± 219 | 688 ± 631 | 816 ± NA |
| Cycle 2: Day 1 | 359 ± 137 | 576 ± 275 | 722 ± 406 | 903 ± NA |
The terminal half-life (t1/2) of DS-1205c alone and in combination with osimertinib was assessed. Pharmacokinetic (PK) parameters for each participant were estimated using non-compartmental analysis. Descriptive statistics are provided for all plasma concentration data by analyte/dose/study day/time and for each PK parameter by analyte/dose/study day, as appropriate.
| hours | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib |
|---|---|---|---|---|
| Cycle 0: Day 1 | 6.98 ± 1.89 | 5.3 ± 1.0 | 4.7 ± 0.6 | 3.3 ± NA |
| Cycle 0: Day 7 | 11.6 ± 6.7 | 7.1 ± 1.0 | 6.9 ± NA | — |
| Cycle 2: Day 1 | 9.8 ± 3.3 | 7.9 ± 0.8 | 7.0 ± 1.3 | 11.7 ± NA |
Collected over Treatment-emergent adverse events (TEAEs) were collected at Screening, Cycle 0 (7-day cycle), Days -1, 1, 2, 4, 6, and 7; Cycle 1 (21-day cycle), Days 4, 8, and 15; Cycle 2 (21-day cycle), Days 1, 2, and 8; Cycle 3 and beyond (21-day cycles), Day 1; and end-of-treatment, 30 days after last dose, up to 1 year.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DS-1205c 200 mg + Osimertinib | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| DS-1205c 400 mg + Osimertinib | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| DS-1205c 800 mg + Osimertinib | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| DS-1205c 1200 mg + Osimertinib | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Event | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/6 | 0/3 | 0/3 | 1/1 |
| Cardiac failureCardiac disorders | 0/6 | 0/3 | 1/3 | 0/1 |
| Coronary artery diseaseCardiac disorders | 0/6 | 0/3 | 1/3 | 0/1 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/6 | 1/3 | 0/3 | 0/1 |
| DysphagiaGastrointestinal disorders | 0/6 | 1/3 | 0/3 | 0/1 |
| PancreatitisGastrointestinal disorders | 0/6 | 0/3 | 1/3 | 0/1 |
| Metastases to MeningesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/6 | 0/3 | 0/3 | 0/1 |
| Alanine aminotransferase increasedInvestigations | 1/6 | 0/3 | 0/3 | 0/1 |
| Aspartate aminotransferase increasedInvestigations | 1/6 | 0/3 | 0/3 | 0/1 |
| Event | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib |
|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 1/6 | 0/3 | 1/3 | 1/1 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 1/3 | 1/3 | 1/1 |
| Aspartate aminotransferase increasedInvestigations | 1/6 | 0/3 | 1/3 | 1/1 |
| Blood creatinine phosphokinase increasedInvestigations | 0/6 | 1/3 | 1/3 | 1/1 |
| Lipase increasedInvestigations | 0/6 | 0/3 | 1/3 | 1/1 |
| PneumoniaInfections and infestations | 1/6 | 0/3 | 0/3 | 1/1 |
| Lymph node painBlood and lymphatic system disorders | 0/6 | 0/3 | 0/3 | 1/1 |
| Traumatic haematomaInjury, poisoning and procedural complications | 0/6 | 0/3 | 0/3 | 1/1 |
| InsomniaPsychiatric disorders | 1/6 | 2/3 | 1/3 | 0/1 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 1/3 | 2/3 | 0/1 |
Demographic and baseline characteristics were assessed in the Full Analysis Set.
| Age, Categorical(Participants) | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 1 | 2 | 0 | 7 |
| >=65 years | 2 | 2 | 1 | 1 | 6 |
| Age, Continuous(years) | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib | Total |
|---|---|---|---|---|---|
| Median | 57.5 (45 to 77) | 73.0 (61 to 88) | 64.0 (63 to 68) | 70 (70 to 70) | 64.0 (45 to 88) |
| Sex: Female, Male(Participants) | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib | Total |
|---|---|---|---|---|---|
| Female | 6 | 2 | 1 | 1 | 10 |
| Male | 0 | 1 | 2 | 0 | 3 |
| Race (NIH/OMB)(Participants) | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 6 | 3 | 3 | 1 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | DS-1205c 200 mg + Osimertinib | DS-1205c 400 mg + Osimertinib | DS-1205c 800 mg + Osimertinib | DS-1205c 1200 mg + Osimertinib | Total |
|---|---|---|---|---|---|
| Taiwan | 6 | 3 | 3 | 1 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
Ran from Apr 2019 to primary completion in Sep 2020, 16 months.
Results were first posted in Jan 2022, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →